Good report with lots of information, it helps understand the...

Good report with lots of information, it helps understand the challenges they are facing in getting the test commericalized - It's more clear to me now that isnt as simple as I first thought it would be.

The Dominincan Republic roll-out is still pending, though the company did annouce invoices were issued to Omics back in April so something is a bit off there.. (https://hotcopper.com.au/threads/ann-appendix-4c-march-2019-quarterly-report.4726933/?source=email)

Lots to digest here, the chairman's note sounds very confident and promosing but that's always the case isnt it? I did like the word "transformational licensing agreements" and then page 12 we see "negotiations on-going" with US partners. - To me this means it's just a matter of getting the best deal possible.

Looks like Mexico & Spain are now pending validation but no timeline provided.

This is paragraph though is priceless:
"It is important to note too, that Janssen Pharmaceuticals, a division of Johnson and Johnson, have now demonstrated thereis a class of drug (gliflozins) able to treat diabetic kidney disease once diagnosed. It is this drug which we are testing incollaboration with our strategic partner Janssen Research and Development. The results from this exciting collaborativestudy are due late this calendar year. If a successful correlation can be established, PromarkerD may become aComplementary Diagnostic (CDx) for such drugs, potentially being utilised every time a prescription is issued."



Source: https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.8b00017

Things are lining up, it's just a timing game now.
Sentiment is a HOLD from me